Tyler Dylan-Hyde Sells 15,000 Shares of Crispr Therapeutics AG (NASDAQ:CRSP) Stock

Crispr Therapeutics AG (NASDAQ:CRSP) insider Tyler Dylan-Hyde sold 15,000 shares of the business’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $18.90, for a total value of $283,500.00. Following the sale, the insider now directly owns 130,204 shares in the company, valued at $2,460,855.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tyler Dylan-Hyde also recently made the following trade(s):

  • On Tuesday, January 2nd, Tyler Dylan-Hyde sold 38,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $21.64, for a total value of $822,320.00.
  • On Friday, December 28th, Tyler Dylan-Hyde sold 700 shares of Crispr Therapeutics stock. The shares were sold at an average price of $21.75, for a total value of $15,225.00.
  • On Friday, December 29th, Tyler Dylan-Hyde sold 31,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $22.72, for a total value of $704,320.00.
  • On Friday, December 22nd, Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $20.55, for a total value of $308,250.00.

Crispr Therapeutics AG (NASDAQ:CRSP) traded up $2.67 on Thursday, hitting $28.44. The stock had a trading volume of 704,463 shares, compared to its average volume of 1,303,695. The company has a market cap of $1,170.00 and a P/E ratio of -88.88. Crispr Therapeutics AG has a 52 week low of $11.63 and a 52 week high of $28.97.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.02). The company had revenue of $2.39 million for the quarter, compared to the consensus estimate of $3.61 million. Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The business’s revenue was up 54.2% compared to the same quarter last year. During the same quarter last year, the company posted ($2.77) EPS. sell-side analysts forecast that Crispr Therapeutics AG will post -2.46 EPS for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its position in shares of Crispr Therapeutics by 459.7% during the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after purchasing an additional 6,560 shares during the last quarter. Capital Investment Advisory Services LLC acquired a new position in shares of Crispr Therapeutics during the 3rd quarter worth about $193,000. Ark Investment Management LLC acquired a new position in shares of Crispr Therapeutics during the 2nd quarter worth about $206,000. Moloney Securities Asset Management LLC acquired a new position in shares of Crispr Therapeutics during the 3rd quarter worth about $235,000. Finally, Vanguard Group Inc. acquired a new position in shares of Crispr Therapeutics during the 2nd quarter worth about $273,000. Institutional investors own 24.52% of the company’s stock.

Several research firms recently weighed in on CRSP. Cann restated a “hold” rating on shares of Crispr Therapeutics in a research note on Sunday, December 10th. BidaskClub downgraded Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. SunTrust Banks restated a “hold” rating and issued a $16.00 target price on shares of Crispr Therapeutics in a research note on Friday, November 10th. Piper Jaffray Companies began coverage on Crispr Therapeutics in a research note on Friday, December 22nd. They issued an “overweight” rating on the stock. Finally, Oppenheimer restated a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, December 21st. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $22.81.

ILLEGAL ACTIVITY WARNING: “Tyler Dylan-Hyde Sells 15,000 Shares of Crispr Therapeutics AG (NASDAQ:CRSP) Stock” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/11/crispr-therapeutics-ag-crsp-insider-tyler-dylan-hyde-sells-15000-shares.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply